Martin Schrappe

Martin Schrappe's AcademicInfluence.com Rankings

Martin Schrappe

Biology

#9360

World Rank

#12557

Historical Rank

Genetics

#955

World Rank

#1051

Historical Rank

Molecular Biology

#1272

World Rank

#1299

Historical Rank

Biochemistry

#1423

World Rank

#1547

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Martin Schrappe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Martin Schrappe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The MLL recombinome of acute leukemias (2006) (751)
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. (2010) (697)
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. (2000) (681)
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. (1994) (660)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. (2015) (644)
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood (1998) (617)
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. (2000) (585)
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. (2007) (536)
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 (2000) (524)
L‐asparaginase treatment in acute lymphoblastic leukemia (2011) (488)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial (2007) (452)
The MLL recombinome of acute leukemias in 2017 (2017) (450)
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 (2010) (447)
New insights to the MLL recombinome of acute leukemias (2009) (417)
The MLL recombinome of acute leukemias in 2013 (2013) (408)
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. (1999) (398)
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region (2002) (385)
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. (2011) (356)
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. (1999) (346)
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. (2000) (337)
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. (2005) (336)
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia (2008) (334)
The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. (2004) (330)
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 (2010) (322)
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias (2011) (321)
BLUEPRINT to decode the epigenetic signature written in blood (2012) (320)
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. (2010) (310)
Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials (1997) (308)
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. (1995) (301)
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. (2008) (291)
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. (2005) (287)
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. (2006) (273)
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study (2012) (273)
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome (2008) (272)
Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. (2001) (270)
How I treat relapsed childhood acute lymphoblastic leukemia. (2012) (269)
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. (2010) (269)
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. (2005) (267)
The impact of age and gender on biology, clinical features and treatment outcome of non‐Hodgkin lymphoma in childhood and adolescence (2005) (262)
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. (2007) (256)
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk (2010) (253)
Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. (2000) (252)
Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. (2014) (243)
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements (2003) (241)
Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. (2003) (240)
Treatment of childhood acute lymphoblastic leukemia. (2009) (236)
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? (2004) (234)
Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. (1998) (231)
Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. (2010) (224)
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. (2007) (222)
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. (2008) (217)
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. (1995) (215)
Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. (2000) (204)
Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. (1994) (203)
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. (2016) (194)
Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study (2005) (185)
TEL-AML1 Fusion Transcript in Relapsed Childhood Acute Lymphoblastic Leukemia (1998) (184)
Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia (2016) (182)
Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. (1992) (182)
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. (2014) (181)
Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children (1996) (177)
Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology (2017) (172)
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options (2015) (171)
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. (2000) (171)
Childhood and adolescent lymphoid and myeloid leukemia. (2004) (167)
Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. (2015) (166)
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. (2005) (164)
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. (2010) (160)
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase (2003) (154)
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. (2002) (154)
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. (2000) (153)
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. (2017) (152)
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting (2007) (149)
Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)—experiences from trial ALL‐BFM 95 (2005) (147)
Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia (2003) (146)
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol (2010) (144)
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. (2013) (144)
Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. (2013) (142)
Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. (2010) (141)
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol (2009) (140)
Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. (1996) (139)
Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. (2013) (138)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. (2019) (137)
XIAP variants in male Crohn's disease (2014) (136)
Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. (2006) (136)
A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. (1996) (135)
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. (2004) (134)
Long-term results of large prospective trials in childhood acute lymphoblastic leukemia (2000) (133)
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. (2010) (129)
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. (2014) (129)
CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. (1998) (127)
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL–BFM 2000 protocol can be separated from FBXW7 loss of function (2010) (126)
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment (2020) (121)
Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. (2006) (120)
Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. (1991) (119)
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement (2007) (118)
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy (2011) (118)
IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. (2018) (117)
Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. (2000) (117)
Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. (2004) (116)
Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group (2000) (116)
Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols (2000) (115)
Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. (2005) (115)
Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. (2015) (113)
High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. (2009) (110)
Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. (1987) (110)
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study (2020) (110)
Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia (2011) (109)
Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). (1999) (108)
[Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. (1987) (107)
Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials (1998) (107)
Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial (2007) (103)
Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations (2010) (103)
The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse (2014) (102)
Outcomes after induction failure in childhood acute lymphoblastic leukemia. (2012) (99)
Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia (2012) (98)
Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. (2008) (98)
Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. (2005) (98)
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia (2012) (96)
Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. (2000) (94)
Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. (1997) (93)
Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform‐specific real‐time polymerase chain reaction approach (2003) (93)
KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia (2015) (93)
Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. (2011) (92)
Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. (2016) (91)
Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations (2012) (91)
Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL (2016) (91)
High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. (2007) (91)
A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report (2017) (89)
Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. (2007) (88)
Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL‐BFM 95 reinduction treatment (2001) (88)
AIEOP‐BFM Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia (2018) (86)
Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. (2013) (86)
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome (2004) (86)
Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. (2003) (85)
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. (1997) (84)
Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: Almost identical MLL breakpoints in therapy‐related AML after treatment without etoposides (2003) (84)
Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. (2011) (83)
Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population (2005) (83)
Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols (2011) (82)
Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. (2015) (81)
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray (2008) (80)
TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Münster Study Group. (1998) (79)
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial (2018) (78)
Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia (2017) (77)
Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. (2003) (76)
Recurrent mutation of JAK3 in T‐cell prolymphocytic leukemia (2014) (75)
Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases (2002) (75)
Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? (2008) (74)
Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case–control study (2007) (73)
Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. (1992) (73)
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study (2016) (72)
Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia (2006) (71)
Varicella vaccination in a child with acute lymphoblastic leukaemia (2007) (71)
Leukemia surfaceome analysis reveals new disease-associated features. (2013) (70)
Evolution of BFM trials for childhood ALL. (2004) (70)
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia (2013) (69)
Long‐term survival of children with leukemia achieved by the end of the second millennium (2001) (69)
Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria (2013) (67)
Optimizing asparaginase therapy for acute lymphoblastic leukemia (2013) (66)
Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia (1998) (66)
Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction (2009) (65)
THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents (2018) (65)
Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes (2002) (65)
Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation (2015) (64)
International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. (2018) (63)
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia (2012) (62)
Frequent loss of heterozygosity on the long arm of chromosome 6: identification of two distinct regions of deletion in childhood acute lymphoblastic leukemia. (1998) (61)
The Seventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Palermo, Italy, January 29–30, 2005 (2005) (60)
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. (2018) (60)
Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1. (1996) (58)
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. (2007) (58)
A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1 (2016) (58)
Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children (2007) (57)
Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. (1996) (57)
Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact (2008) (57)
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). (2017) (57)
The SIOPE strategic plan: a European cancer plan for children and adolescents (2015) (56)
Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL‐BFM treatment protocols (1999) (56)
ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia (2015) (55)
GSTP1 and MDR1 Genotypes and Central Nervous System Relapse in Childhood Acute Lymphoblastic Leukemia (2005) (55)
Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen‐breakage syndrome): a retrospective survey (2011) (54)
Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks (2006) (53)
Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials (2008) (53)
Detection and management of minimal residual disease in acute lymphoblastic leukemia. (2014) (53)
Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS). (2015) (53)
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor a (2017) (52)
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome (2017) (52)
Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop (2004) (51)
Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma (2017) (51)
The 'Survivorship Passport' for childhood cancer survivors. (2018) (50)
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. (2011) (50)
Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2018) (50)
Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment (2020) (49)
Constitutive expression levels of CD95 and Bcl‐2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia (2000) (49)
A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL (2003) (49)
Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. (2005) (48)
‘Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985–2000)’ (2010) (47)
Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients (2006) (47)
Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. (2019) (47)
Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000) (2008) (47)
Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia (2007) (46)
Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From 1981 to 2000 (2013) (46)
In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. (2002) (46)
Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts (2005) (45)
Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. (2001) (45)
Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL‐SCT 2003/2007 trial (2018) (45)
Therapeutic drug monitoring of asparaginase in the ALL‐BFM 2000 protocol between 2000 and 2007 (2010) (45)
Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient. (2012) (44)
Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group. (1998) (43)
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. (2006) (43)
A prospective study of minimally invasive techniques in pediatric surgical oncology: preliminary report. (2003) (43)
Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk (2019) (43)
Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols (2017) (43)
Treatment outcome of CRLF2 ‐rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP‐BFM and UK NCRI‐CCLG study groups (2012) (43)
Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group. (1996) (43)
Central nervous system acute lymphoblastic leukemia: role of natural killer cells. (2015) (42)
Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. (2003) (42)
ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia (2014) (42)
Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia (2011) (41)
Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia. (2011) (41)
Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. (1992) (41)
Detection of minimal residual disease identifies differences in treatment response between TALL and precursor BALL (2002) (40)
Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia (2016) (39)
Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. (2009) (39)
The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system (2017) (39)
Challenges for children and adolescents with cancer in Europe: The SIOP-Europe agenda (2014) (38)
NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. (2004) (38)
MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen (2001) (37)
Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation (2019) (37)
Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. (1998) (37)
Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia. (2003) (36)
All children have a right to full access to treatment for cancer (2004) (36)
Mutations of JAK 2 in acute lymphoblastic leukaemias associated with Down ’ s syndrome (2008) (36)
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias (2011) (36)
High incidence and unique features of antigen receptor gene rearrangements in TEL–AML1-positive leukemias (2004) (35)
Single-cell analysis of structural variations and complex rearrangements with tri-channel processing (2019) (35)
Detection of hyperdiploid karyotypes (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) using fluorescence in situ hybridization (FISH) (1998) (35)
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. (2019) (35)
Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia (2018) (34)
Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia (2010) (34)
Mutation analysis of CD95 (APO‐1/Fas) in childhood B‐lineage acute lymphoblastic leukaemia (1998) (34)
PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia (2019) (33)
Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry (2010) (33)
Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia (2003) (33)
The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia (2004) (33)
The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients (2013) (33)
PEG-asparaginase (Oncaspar) 2500 U/m2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols (2002) (33)
Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group. (2007) (32)
No evidence for a major role of heterozygous deletion 657del5 within the NBS1 gene in the pathogenesis of non‐Hodgkin's lymphoma of childhood and adolescence (2000) (32)
IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia. (2018) (32)
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. (2019) (32)
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol (2014) (31)
ALMOST NORMAL COGNITIVE FUNCTION IN PATIENTS DURING THERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA WITHOUT CRANIAL IRRADIATION ACCORDING TO ALL-BFM 95 AND COALL 06-97 PROTOCOLS: Results of an Austrian–German Multicenter Longitudinal Study and Implications for Follow-Up (2007) (31)
Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia (2009) (31)
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol (2016) (31)
Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia (2020) (30)
PDX models recapitulate the genetic and epigenetic landscape of pediatric T‐cell leukemia (2018) (30)
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol (2017) (30)
The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. (2019) (30)
Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: significance and therapy response. (2002) (30)
Intermediate Dose Methotrexate Is as Effective as High Dose Methotrexate in Preventing Isolated Testicular Relapse in Childhood Acute Lymphoblastic Leukemia (1998) (29)
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. (2017) (29)
Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. (2006) (29)
Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment (2011) (29)
The eighth international childhood acute lymphoblastic leukemia workshop (‘Ponte di Legno meeting’) report: Vienna, Austria, April 27–28, 2005 (2006) (29)
Lmo2 expression defines tumor cell identity during T‐cell leukemogenesis (2018) (29)
Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome (2013) (28)
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols (2019) (28)
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia (2008) (28)
Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood (2017) (26)
Preexisting conditions in pediatric ALL patients: Spectrum, frequency and clinical impact. (2016) (26)
Advances in therapy for Philadelphia‐positive acute lymphoblastic leukaemia of childhood and adolescence (2016) (26)
Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia (2016) (26)
Identification of three distinct regions of deletion on the long arm of chromosome 11 in childhood acute lymphoblastic leukemia (1999) (25)
An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts. (2017) (25)
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B‐cell acute lymphoblastic leukaemia in children (2018) (25)
Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. (2006) (25)
Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease (2008) (25)
Clinical characteristics and treatment outcome of infants with non‐Hodgkin lymphoma (2007) (25)
No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities (2005) (25)
Immunophenotypic and clinical features of T‐cell receptor γδ+ T‐lineage acute lymphoblastic leukaemia (1998) (25)
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A (2015) (25)
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol (2020) (25)
Pharmacokinetics of high‐dose methotrexate in infants treated for acute lymphoblastic leukemia (2009) (25)
Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment. (2012) (25)
Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome (2012) (24)
DNA methylation profiling of pediatric B‐cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites (2017) (24)
Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients (2014) (24)
Neurotoxic side effects in children with refractory or relapsed T‐cell malignancies treated with nelarabine based therapy (2017) (24)
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study (2019) (24)
Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia (1998) (24)
Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy (2001) (23)
Lineage Classification of Childhood Acute Lymphoblastic Leukemia according to the EGIL Recommendations: Results of the ALL-BFM 2000 Trial (2013) (23)
Comparative genomic hybridization in childhood acute lymphoblastic leukemia: correlation with interphase cytogenetics and loss of heterozygosity analysis. (2001) (22)
Effective treatment of infantile choriocarcinoma in the liver with chemotherapy and surgical resection: a case report. (2000) (22)
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia (2014) (22)
Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL‐negative acute lymphoblastic leukemia (2013) (22)
Polymorphisms within glutathione S-transferase genes in pediatric non-Hodgkin's lymphoma. (2002) (22)
CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (2017) (22)
Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy (2001) (21)
Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance (2006) (21)
PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. A PROSPECTIVE STUDY OF THE INTERNATIONL BFM STUDY GROUP. (1998) (21)
Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The ‘big sister’ of the infant disease? (2007) (21)
Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016) (2018) (21)
Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study (2014) (21)
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group (2007) (21)
Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia. (2004) (20)
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. (2021) (20)
Immunosurveillance of childhood ALL: polymorphic interferon-γ alleles are associated with age at diagnosis and clinical risk groups (2005) (20)
Heterogeneous expression pattern of pro‐ and anti‐apoptotic factors in myeloid progenitor cells of patients with severe congenital neutropenia treated with granulocyte colony‐stimulating factor (2005) (20)
Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma. (2013) (20)
Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia. (2009) (20)
ACUTE LYMPHOBLASTIC LEUKEMIA AND KLINEFELTER SYNDROME IN CHILDREN: Two Cases and Review of the Literature (2004) (19)
Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time (2008) (19)
Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures (2019) (19)
Prognostic relevance of dic(9;20)(p11;q13) in childhood B‐cell precursor acute lymphoblastic leukaemia treated with Berlin‐Frankfurt‐Münster (BFM) protocols containing an intensive induction and post‐induction consolidation therapy (2010) (19)
Minimal Residual Disease–based Treatment is Adequate for Relapse-prone Childhood Acute Lymphoblastic Leukemia with an intrachromosomal amplification of chromosome 21: The experience of the ALL-BFM 2000 trial (2014) (19)
Anemia and survival in childhood acute lymphoblastic leukemia (2008) (19)
The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia (2021) (19)
A genome-wide association study identi fi es risk loci for childhood acute lymphoblastic leukemia at 10 q 26 . 13 and 12 q 23 . 1 (2017) (19)
CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. (2010) (19)
T‐cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases (2017) (18)
Prognostic relevance of TLX3 (HOX11L2) expression in childhood T‐cell acute lymphoblastic leukaemia treated with Berlin–Frankfurt–Münster (BFM) protocols containing early and late re‐intensification elements (2010) (18)
Prognostic factors in childhood acute lymphoblastic leukemia (2003) (18)
Impact of the COVID-19 pandemic on incidence, time of diagnosis and delivery of healthcare among paediatric oncology patients in Germany in 2020: Evidence from the German Childhood Cancer Registry and a qualitative survey (2021) (18)
Long-term study of the clinical significance of loss of heterozygosity in childhood acute lymphoblastic leukemia (2003) (17)
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia (2020) (17)
Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia (2002) (17)
Lack of expression of the chondroitin sulphate proteoglycan neuron‐glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11) (2006) (17)
Statement by members of the Ponte di Legno group on the right of children with leukemia to have full access to essential treatment for acute lymphoblastic leukemia. (2004) (17)
[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL]. (1994) (17)
New treatment strategies in childhood acute lymphoblastic leukaemia. (2002) (16)
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. (2022) (16)
Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia (2015) (15)
Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene. (2006) (15)
Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. (2014) (15)
Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. (2021) (15)
The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, May 6-7, 2009 (2009) (15)
Flow‐cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B‐cell precursor acute lymphoblastic leukemia in trial AIEOP‐BFM‐ALL 2000 (2019) (15)
Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study. (2005) (15)
Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL (2019) (15)
Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia (2017) (15)
Therapeutic Drug Monitoring of Asparaginase Activity—Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial (2017) (15)
Prognostic impact of IKZF1 deletions in association with vincristine–dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95 (2017) (15)
CD 95 ( APO-1 / Fas ) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia (1998) (15)
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial (2019) (14)
An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report (2021) (14)
Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment (2010) (14)
High-dose methotrexate: pharmacokinetics in children and young adults. (1988) (14)
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor (2018) (14)
Prediction of Outcome by Early Response in Childhood Acute Lymphoblastic Leukemia (2013) (14)
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. (2020) (14)
What has to be considered in HIV positive Patients undergoing acute and elective Operations (1993) (13)
‘Ponte di Legno’ Working Group – Report on the Fifth International Childhood Acute Lymphoblastic Leukemia Workshop: Vienna, Austria, 29 April – 1 May 2002 (2003) (13)
NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemia. (2018) (13)
Does megatherapy contribute to survival in metastatic neuroblastoma? A retrospective analysis. German Cooperative Neuroblastoma Study Group. (1997) (12)
RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts (2016) (12)
Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study (2009) (12)
Expression of CD56 defines a distinct subgroup in childhood T‐ALL with inferior outcome. Results of the ALL‐BFM 2000 trial (2018) (12)
The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia (2017) (12)
MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. (2021) (11)
[The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases]. (1998) (11)
Outcome of Infants Less Than One Year of Age with Acute Lymphoblastic Leukemia Treated with the Interfant-99 Protocol. (2006) (11)
[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group]. (1994) (11)
A case–control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF‐β and receptor genes (2009) (11)
Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000) (2016) (11)
Research recommendations toward a better understanding of the causes of childhood leukemia (2011) (11)
Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia (2009) (11)
Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia (2018) (11)
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. (2019) (11)
Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia (2020) (11)
Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high‐risk or relapsed ALL – results of the ALL‐SCT 2003 trial (2018) (11)
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia (2021) (10)
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. (2020) (10)
Current Status and Future Perspectives of Chemoimmunoconjugates for the Treatment of Cancer (1990) (10)
Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients (2018) (10)
No Influence on the Incidence of Osteonecroses When Dexamethasone Replaces Prednisone during Induction Treatment for Childhood ALL: Results of Trial ALL-BFM 2000. (2008) (10)
A European paediatric cancer mission: aspiration or reality? (2019) (10)
MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB (2018) (10)
The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7–9, 2011 (2013) (10)
Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS) (2020) (10)
The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia (2005) (10)
Methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism and risk of pediatric non-Hodgkin lymphoma in a German study population. (2005) (9)
Long term survival in children with acute leukaemia and complications requiring mechanical ventilation (2011) (9)
Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines (2015) (9)
Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia – first findings of the OPAL trial (2017) (9)
Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. (2008) (9)
Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study. (2007) (9)
Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy (2019) (9)
Quantitative Monitoring of Minimal Residual Disease after Allogeneic Stem Cell Transplantation in Relapsed Childhood ALL Allows the Identification of Impending Relapse – Results of the ALL BFM SCT 2003 Trial (2014) (9)
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia (2018) (8)
Emergence of translocation t(9;11)‐positive leukemia during treatment of childhood acute lymphoblastic leukemia (2004) (8)
Risk Adapted Treatment in Childhood Acute Lymphoblastic Leukemia: Data from the Berlin-Frankfurt-Münster Group (1997) (8)
Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors (2020) (8)
Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo (2015) (8)
Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen (2018) (8)
Immunophenotypic and clinical features of T-cell receptor gammadelta+ T-lineage acute lymphoblastic leukaemia. (1998) (8)
[Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81]. (1987) (8)
CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia. (2018) (8)
Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes. (2005) (8)
Immunosurveillance of childhood ALL - Polymorphic Interferon-γ alleles are associated with age at diagnosis and clinical risk groups (2004) (8)
TNFR2 is required for RIP1-dependent cell death in human leukemia. (2020) (8)
Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia (2021) (8)
Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin–Frankfurt–Münster Study Group (2015) (8)
Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia (2004) (8)
Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP‐BFM acute lymphoblastic leukemia protocol (2020) (8)
Efficacy and Safety of Imatinib on Top of BFM-Like Chemotherapy in Pediatric Patients with Ph+/BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL). the EsPhALL Study (2011) (7)
Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network (2019) (6)
Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study (2018) (6)
Chromosome-Positive ( Ph 1 ) Childhood Acute Lymphoblastic Leukemia : Good Initial Steroid Response Allows Early Prediction of a Favorable Treatment Outcome (1998) (6)
Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial (2010) (6)
Prospective Study on Allogeneic Bone Marrow Transplantation (Allo BMT) versus Chemotherapy (Chemo) for Very High-Risk (VHR) Childhood Acute Lymphoblastic Leukaemia in First Complete Remission (2001) (6)
INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA (2015) (6)
[Antiretroviral therapy in adult HIV-infected patients]. (1994) (6)
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol (2021) (6)
The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment (2014) (6)
Imperative of continual support by the European Community for future advances in paediatric oncology in Europe: meeting report of the EC-funded science-communication project DIRECT “Overcoming Cancer with Research” (2009) (6)
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. (2000) (6)
Activating NOTCH1 Mutations Predict Favorable Early Treatment Response and Long Term Outcome in Child- hood Precursor T-Cell Lymphoblastic Leukemia Short Title: NOTCH1mutations predict outcome in pediatric T-ALL (2006) (6)
[Acute leukemia in childhood. Classification--diagnosis--therapy--prognosis]. (1996) (5)
CD 11 b is a therapy resistance – and minimal residual disease – specific marker in precursor B-cell acute lymphoblastic leukemia (2010) (5)
Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group (2011) (5)
The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. (2020) (5)
Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. (2016) (5)
Prospective Evaluation of MRD-Kinetics in 274 Children with High-Risk ALL Treated in Trial ALL-BFM 2000: Insights into Development of Resistance and Impact on Further Refinement of Treatment Stratification Strategies. (2007) (5)
TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia (2019) (5)
Results of the Randomized I-BFM-SG Trial „Acute Lymphoblastic Leukemia Intercontinental-BFM 2002“ in 5060 Children Diagnosed in 15 Countries on 3 Continents (2011) (5)
No association between the presence of killer-cell immunoglobulin-like receptor genes and susceptibility to childhood ALL. (2015) (5)
Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol (2019) (5)
Collaboration between Activating Mutations in JAK2 and Trisomy 21 in the Acute Lymphoblastic Leukemias of Down Syndrome (DS). (2007) (5)
Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients (2015) (5)
Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics (2021) (5)
Temporal changes of the incidence of childhood cancer in Germany during the COVID-19 pandemic: Updated analyses from the German Childhood Cancer Registry (2022) (4)
Second malignancies after treatment of childhood non-Hodgkin lymphoma – a report of the Berlin-Frankfurt-Muenster study group (2020) (4)
Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group (2008) (4)
The 9 p 21 . 3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN 2 A (2015) (4)
Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002 (2011) (4)
Therapeutic drug monitoring of asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-asparaginase in the AIEOP-BFM ALL 2009 study. (2020) (4)
Concurrent deIetions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 (IKZF1plus) confer a very poor prognosis in pediatric acute lymphoblastic leukemia (2014) (4)
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data (2021) (3)
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. (2019) (3)
Outcome of Treatment for Relapsed Acute Lymphoblastic Leukemia in Children with Down Syndrome (2012) (3)
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL). (2009) (3)
Early Diagnosis and Molecular-Based Treatment of Very Highly Resistant Acute Lymphoblastic Leukemia in Childhood (2008) (3)
Prospective Evaluation of Thromboembolic Events During Chemotherapy of Childhood Acute Lymphoblastic Leukemia: Results of Randomized Trial ALL-BFM 2000. (2009) (3)
Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia. (2007) (3)
Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies (2016) (3)
Current Treatment Approaches in Childhood Acute Lymphoblastic Leukemia (2010) (3)
The BH3-Mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy. (2007) (3)
Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia (2016) (3)
Disease Propagating Blasts in Standard and High Risk Acute Lymphoblastic Leukemia Are Frequent and of Diverse Immunophenotype (2009) (3)
The Favorable Effect of Activating NOTCH1 Receptor Mutations On Long Term Outcome in T-ALL Is Treatment Related and Can Be Separated From NOTCH Pathway Activation by FBXW7 Loss of Function. (2009) (3)
An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) (2009) (3)
THE 15–20 YEAR OLD PATIENTS WITH NHL TREATED IN FRANCE: DATA OF CHILDHOOD AND ADULT DATABASES (2005) (3)
Leukemia-Initiating Cells Are Frequent in Very High Risk Childhood Acute Lymphoblastic Leukemia and Give Rise to Relatively Stable Phenotypes in Immunodeficient Mice. (2009) (3)
Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000. (2007) (3)
Genetic Variation in ABCC4 and CFTR and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia (2021) (2)
Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life (2000) (2)
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. (2017) (2)
Paediatric Cancer Predisposition Documentation Tool – Standardized Reporting Form for Children and Adolescents With Suspected Cancer Predisposition Syndrome (2021) (2)
High Interleukin 15 Expression Characterizes Childhood Acute Lymphoblastic Leukemia with Involvement of the Central Nervous System. (2006) (2)
Repurposing anthelmintic agents to eradicate resistant leukemia (2020) (2)
T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial (2016) (2)
[Fever in immunosuppressed patients]. (1995) (2)
Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95. (2004) (2)
Foscarnet 5 versus 7 days a week treatment for severe gastrointestinal CMV disease in HIV-infected patients (1996) (2)
Cryptic TCF3 fusions in childhood leukemia - detection by RNA-sequencing. (2021) (2)
CNS Involvement in Childhood and Adolescence Non-Hodgkin Lymphoma: Prevalence and Patient’s Outcome Differ According to the Subtype. (2005) (2)
A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia: A Single-Arm, Intergroup Study (Esphall 2010) (2018) (2)
More and better cure for an orphan: priorities for future paediatric cancer research in Europe – Meeting report of the EC-funded science-communication project DIRECT “Overcoming Cancer with Research” (2009) (2)
Multicentric ALL-BFM 2000 Trial: Evaluation of the quality of cranial radiotherapy in childhood acute lymphatic leukemia. (2004) (2)
Antibody-Drug Conjugates for Cancer Therapy (1991) (2)
The gene expression classifier ALLCatchR identifies B-precursor ALL subtypes and underlying developmental trajectories across age (2023) (2)
Frequent Loss of Heterozygosity on Chromosomes 6q, 9p, 11q or 12p in Childhood Acute Lymphoblastic Leukemia (1998) (2)
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009 (2022) (2)
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia (2021) (2)
Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report (2014) (2)
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study (2022) (2)
Zeta-Chain-Associated Protein Kinase-70 (Zap-70) Promotes Acute Lymphoblastic Leukemia (ALL) Infiltration into the Central Nervous System By Enhancing Chemokine Receptor 7 (CCR7) Expression (2015) (2)
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution (2022) (2)
TGF-β signaling causes ALL quiescence (2013) (1)
Time to Failure and CD3-Expression Are Strong Prognostic Factors in Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence. (2005) (1)
Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study. (2008) (1)
C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia (2010) (1)
Lebendspende-Lebertransplantation beim Kind (2010) (1)
Very Early/Early Relapses of ALL Show Unexpected Changes of Clonal Markers and High Heterogeneity in Initial and Relapse Treatment Response: ALL-BFM 2000 and ALL-REZ BFM 96/2002 . (2009) (1)
NOTCH1 Activation Neutralizes the Unfavorable Prognostic Effect of PTEN Mutations in BFM-Treated Children with T-ALL (2011) (1)
Drug Response Profiling to Identify Selective Pharmacological Activity in Drug Resistant ALL (2015) (1)
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease (2022) (1)
Frequent Loss of the SLP-65 Adapter Protein in Childhood Acute B-Precursor Lymphoblastic Leukemia (ALL) with TEL/AML1 Rearrangement. (2005) (1)
Analyses of a Pair of Concordant Twins with Infant ALL and Discordant Clinical Outcome Reveals Immunoescape As a Mechanism of Disease Persistence in MLL-Rearranged Leukemia (2014) (1)
Constitutive Activation of FLT3 Is a Positive Prognostic Factor in Infants with MLL-Rearranged Acute Lymphoblastic Leukemia (2015) (1)
Molecular Targets of Glucocorticoids in Context of Apoptosis Induction in Childhood Precursor T-Cell ALL (T-ALL). (2004) (1)
Workshop on Minimal Residual Disease (2001) (1)
[Living donation liver transplantation in children]. (2010) (1)
Ikzf1 Deletion Status Discriminates For Outcome In Imatinibtreated Bcr-Abl1-Positive Childhood ALL (2013) (1)
A Molecular Signature of the Transcription Factor GATA1 in Acute Megakaryoblastic Leukemia of Childhood. (2004) (1)
GENOMIC AND DRUG RESPONSE PROFILING OF FATAL TCF3-HLF-POSITIVE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IDENTIFIES RECURRENT MUTATION PATTERNS AND NOVEL THERAPEUTIC OPTIONS (2015) (1)
Relapse in Childhood “Very High Risk” Acute Lymphoblastic Leukemia Treated with BFM Chemotherapy Has a Dismal Outcome Even When Treated with Transplantation. (2008) (1)
response in childhood acute lymphoblastic leukemia Distinct gene expression profiles determine molecular treatment (2004) (1)
Bilateral Involvement Is an Independent Risk Factor in Testicular Relapse of Childhood ALL: Results of the Trials ALL-REZ BFM 83 - 2002 (2014) (1)
Near-tetraploid T-cell acute lymphoblastic leukaemia in childhood: Results of the AIEOP-BFM ALL studies. (2022) (1)
Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2018) (1)
Cytochrome C Related Caspase Activation Determines Treatment Response in Childhood B- Precursor ALL. (2004) (1)
Clinical Implication of BCR/ABL Fusion Transcript Monitoring in Addition to Ig/TCR Gene Rearrangement-Based Minimal Residual Disease in Philadelphia Chromosome-Positive Childhood Acute Lymphoblastic Leukemia (2014) (1)
Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000 (2011) (1)
A Randomized Phase-I 11 Study of the Efficacy of Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia (2002) (1)
Acute Lymphoblastic Leukaemia (2004) (1)
A DNA-Based RQ-PCR Screening Assay for the Identification of Cases with RUNX1 Copy Number Changes in Childhood B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). (2005) (1)
Detection of minimal residual disease in T-ALL and in precursor-B-ALL (2001) (1)
Pediatric T-Cell Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma: Differences in the Common Deleted Region and the Prognostic Impact of Chromosome 6q Deletions. (2006) (1)
School and kindergarten attendance and home schooling of pediatric cancer patients before and during the SARS-CoV-2 pandemic: results of a survey of the German Society for Pediatric Oncology and Hematology (2021) (1)
Two subgroups of CRLF2-overexpressing pediatric acute lymphoblastic leukemias differ in outcome and gene expression (2014) (1)
CD79a Is Associated with Central Nervous System Infiltration of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia (2018) (1)
[Antiinfectious prophylaxis in pediatric oncology. Work group "Quality Assurance" of Society for Pediatric Oncology and Hematology (GPOH)]. (1999) (1)
A Case of Concordant Twins with Infant ALL and Discordant Clinical Outcome – Part I: the genetic basis – identification of DSC2 as a gene with prognostic impact in infant MLL-rearranged ALL (2015) (1)
Treatment Response and Outcome in Childhood t(1;19)/TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group. (2005) (1)
Proteasome Inhibitor Bortezomib Induces Apoptosis in Prednisone-Resistant Childhood Acute Lymphoblastic Leukemia Cells. (2009) (1)
Group report event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Intensive ALL-type therapy without local radiotherapy provides a 90% (2013) (1)
Reduction of Treatment Related Mortality After Stem Cell Transplantation In Children and Adolescents with all Undergoing Allogeneic Stem Cell Transplantation: The Value Of Severe Adverse Event Reporting (2009) (1)
Treatment response and residual-disease monitoring in initial and relapsed TEL-AML1 positive childhood ALL (2001) (1)
Heterogeneity of treatment outcome in children with Philadelphia chromosome-positive acute lymphoblastic leukemia (1999) (1)
Proteasome inhibitor bortezomib induces apoptosis in prednisone-resistant childhood acute lymphoblastic leukemia cells (2010) (1)
Multicentric ALL-BFM 2000 Trial: Evaluation of the quality of cranial radiotherapy in childhood acute lymphatic leukemia (2004) (1)
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis (2018) (1)
RISK ASSESSMENT IN CHILDHOOD AND ADOLESCENT ACUTE LYMPHOBLASTIC LEUKEMIA (2004) (1)
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Prednisone Response Is the Strongest Predictor of Treatment Outcome in Infant Acute Lymphoblastic Leukemia (2016) (0)
leukemia and long term outcome in child-hood precursor T-cell lymphoblastic Activating NOTCH1 mutations predict favorable early treatment response (2013) (0)
In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients (2020) (0)
93 Risk adapted treatment for childhood ALL: the BFM experience (2003) (0)
A Case of Concordant Twins with Infant ALL and Discordant Clinical Outcome – Part II: highlights on an immunoescape phenotype as a potential mechanism of disease persistence (2015) (0)
Case forum: Cutaneous manifestation of JMML without monocytosis in a newborn child (2006) (0)
Bornhauser B, Cario G, Rinaldi A, et al. The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Adv. 2020;4(17):4052-4064. (2022) (0)
MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB (2018) (0)
Nasoenteral nutrition for HIV associated wasting - promise and outcome (1995) (0)
TP53 single nucleotide variants (SNV) in patients developing second malignant neoplasms after treatment for childhood acute lymphoblastic leukemia (2016) (0)
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia (2021) (0)
Monitoring of Minimal Residual Disease After Allogeneic Stem Cell Transplantation In Relapsed Childhood ALL Allows The Identification Of Impending Relapse - Results Of The ALL BFM SCT 2003 Trial (2013) (0)
Paediatric leukaemia — Is there a continuing role for radiation therapy (1998) (0)
Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol (2022) (0)
[Erratum to: DKG certification of paediatric cancer centres - a wide field …]. (2020) (0)
Prediction of minimal residual disease in pediatric ALL: Comparison and evaluation of different mathematical methods applied to data from the ALL-BFM 2000 trial (2014) (0)
Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL) (2008) (0)
Whole Exome Sequencing In Relapsed Pediatric T-ALL: Progression Into Relapse Is Characterized By An Increased Number Of Somatic Mutations and a Conservation Of Mutations In Leukemogenic Driver Genes (2013) (0)
104 INVITED Relapsed Acute Lymphoblastic Leukemia (2011) (0)
Abstract 5330: Leukemia initiating cells are frequent and oligoclonal in de novo resistant ALL (2011) (0)
Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation (2016) (0)
Regulating the activity of p38α/β as a potential therapy against childhood acute lymphoblastic leukemia (2014) (0)
High-Resolution Genomic Profiling (array-CGH) of Childhood T-ALL Identifies Deletions at 6q15-16.1 as a Predictive Marker for Early Treatment Response. (2008) (0)
Minimal Residual Disease Detection Identifies Differences between the Risk Groups Defined by the ALL IC-BFM 2002 and the ALL-BFM 2000 Protocols. (2004) (0)
TREATMENT OF CHILDHOOD ALL 3123 an increased leukemic cell (2002) (0)
Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol (2021) (0)
Gene Expression in Leukemic Blasts Persisting at Day 8 of Induction Therapy in Childhood ALL Displays a Common Shift towards Terminally Differentiated B Cells and a Cytoreduction-Associated Impairment of the Translational Machinery. (2005) (0)
Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. (2023) (0)
Unsupervised Analysis of Human Leukemia Cells Identifies the Valosin-Containing Protein as a Putative Marker for Glucocorticoid Resistance. (2004) (0)
An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse (2022) (0)
Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group (2023) (0)
Immunotherapeutic co-targeting of CD38 and CD47 in T-cell acute lymphoblastic leukemia (T-ALL) (2020) (0)
Impact of the gene expression of natural killer cell receptors and their ligands for treatment response and prognosis in pediatric acute lymphoblastic leukemia (2016) (0)
Differential Gene Expression in Leukemic Cells from Bone Marrow (BM) and Peripheral Blood (PB) of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL). (2004) (0)
Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes (2018) (0)
Can Bortezomib Treatment Overcome Glucocorticoid Resistance of Childhood Acute Lymphoblastic Leukemia Cells (2007) (0)
Genetic modifiers in Immune thrombocytopenic purpura (ITP) - Single nucleotide polymorphism (SNP) data on 60 children with chronic ITP (2011) (0)
Activating NOTCH1 Mutations Are Associated with Good Treatment Response in Childhood T-Cell Acute Lymphoblastic Leukemia. (2005) (0)
Treating childhood leukemia without cranial irradiation. (2009) (0)
Prognostic impact of FLT3 gene expression and mutational status in pediatric MLL-rearranged ALL (2014) (0)
Allogeneic HSCT from Unrelated and Sibling Donors are Equal for Children with Acute Lymphoblastic Leukemia (2013) (0)
Early diagnosis and targeted treatment of very high-risk childhood acute lymphoblastic leukaemia (2009) (0)
New Insights into Potential Driver Mutations in Pediatric Burkitt Lymphoma (2014) (0)
Repurposing anthelmintic agents to eradicate resistant leukemia (2020) (0)
Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study Group. (2009) (0)
Deletion in Childhood Acute Lymphoblastic Leukemia Chromosome 6 : Identification of Two Distinct Regions of Frequent Loss of Heterozygosity on the Long Arm of Updated (2006) (0)
171 INVITED The European Network for Cancer Research in Children and Adolescents(ENCCA) FP7 Project (2011) (0)
The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action (2022) (0)
Early Diagnosis and Targeted Treatment of Very High-Risk Childhood Acute Lymphoblastic Leukemia – The I-BFM Approach (2011) (0)
LYMPHOID NEOPLASIA IKZF 1 status as a prognostic feature in BCR-ABL 1 – positive childhood ALL (2014) (0)
[Clinical aspects and therapy of ubiquitous mycobacterioses]. (1995) (0)
High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients (2011) (0)
THE EUROPEAN ROADMAP TO HORIZON 2020 FOR CHILDREN AND ADOLESCENTS WITH CANCER - A LONG TERM SUSTAINABLE STRATEGY (2015) (0)
Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia (2011) (0)
Brief report Veriﬁcation of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood (2010) (0)
Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia (2016) (0)
Secondary brain tumours in children with ALL (1999) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2019) (0)
Osteonecrosis after Allogeneic HSCT in Children with High-Risk or Relapsed ALL Treated in the ALL-SCT 2003 Trial (2017) (0)
The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients (2012) (0)
Early treatment sensitivity in childhood acute lymphoblastic leukemia is associated with gain of chromosome 21. (2006) (0)
Invasive Fungal Infections in Pediatric Acute Lymphoblastic Leukemia: Incidence, Characterization, Outcome and Risk Analysis of Study ALL-BFM 2000 (2014) (0)
Monitoring of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia — Preliminary Data from a Prospective Study (1998) (0)
Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures (2019) (0)
Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL (2016) (0)
Incidence and genetic characterization of childhood acute lymphoblastic leukemia with CRLF2 overexpression treated according to the AIEOP-BFM ALL 2009 protocol (2015) (0)
Role of three childhood acute lymphoblastic leukemia-associated SNPs in a pediatric non-Hodgkin lymphoma cohort (2012) (0)
An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse (2022) (0)
S108: PEDIATRIC T- ALL RELAPSE: CONSTITUTIONAL CANCER PREDISPOSITION AND HYPERMUTATATOR PHENOTYPES (2022) (0)
285 Tailored treatment of childhood ALL (2009) (0)
Genome-wide associations of genetic variation with minimal residual disease in ETV6-RUNX1-positive childhood acute lymphoblastic leukemia (2011) (0)
Does the Y chromosome play a role for outcome in childhood acute lymphoblastic leukemia? (2022) (0)
Prediction of minimal residual disease in pediatric ALL: Evaluation of the predictive potential of the variables from the ALL-BFM 2000 trial (2013) (0)
Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia (2009) (0)
Significance of Copy Number Alterations for Molecular Treatment Response in Childhood Acute Lymphoblastic Leukemia. (2007) (0)
IL7R Targeting Using OSE-127 Shows Robust Anti-Leukemic Activity in B-Cell Precursor Acute Lymphoblastic Leukemia Xenografts (2021) (0)
Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000 (2017) (0)
Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia (2022) (0)
CD11b Is a Therapy-Induced Marker for Monitoring Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. (2007) (0)
Thirty Percent Long Term Survival In Children with Acute Leukemia and Complications Requiring Mechanical Ventilation (2010) (0)
A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups (2022) (0)
ACCELERATE and EMA Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children Authors (2019) (0)
Identification of germline polymorphisms associated with clinical and toxicity phenotypes in childhood acute lymphoblastic leukemia (2013) (0)
Treatment of Severe Acute GvHD with Alemtuzumab Is Effective without Increased Relapse Rates (2019) (0)
pathway lymphoblastic leukemia cells to dexamethasone via an Akt-dependent Low dose arsenic trioxide sensitizes glucocorticoid-resistant acute (2013) (0)
HG-34HIGH-GRADE GLIOMA ARISING IN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC MALIGNANCIES: A COOPERATIVE ANALYSIS OF THE GERMAN HIT-HGG/-GBM AND ALL-BFM/COALL STUDIES (2016) (0)
[Updated AWMF Guideline on the Diagnosis and Treatment of Acute Lymphoblastic Leukaemia in Children]. (2022) (0)
Whole-Exome-Sequencing identifiziert hohe Plastizität, Selektionsdruck und „druggable targets“ in Leukämiezellen pädiatrischer ALL Rezidive nach allogener Stammzelltransplantation (2018) (0)
Clinical and molecular characterization of therapy-related myeloid neoplasms after treatment for childhood acute lymphoblastic leukemia (2010) (0)
Glucocorticoid Therapy Targets Proliferation, Differentiation and Bcl-2 Dependent Survival Signaling in ALL Blasts. (2006) (0)
Targeting CD38 in T-ALL using a novel Fc-engineered antibody (2018) (0)
BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease (2022) (0)
Diagnostic C erebrospinal F luid E xamination i n C hildren W ith Acute L ymphoblastic L eukemia: S ignificance o f L ow L eukocyte Counts W ith B lasts o r T raumatic L umbar P uncture (2003) (0)
Minimal residual disease analysis in children with t ( 12 ; 21 )-positive acute lymphoblastic leukemia : comparison of Ig / TCR rearrangements (2006) (0)
Evidence for Cooperation of Receptor Tyrosine Kinases and Activating NOTCH Mutations to Hyperactivate mTOR in T-Cell Leukemia: A Rationale Basis for Targeted Therapy (2011) (0)
Clinical Goals of Targeted Therapy in Childhood ALL (2011) (0)
Acute lymphoblastic leukemia (2018) (0)
Single-cell analysis of structural variations and complex rearrangements with tri-channel processing (2019) (0)
Activation of Simultaneous Apoptosis and Necroptosis to Eradicate Drug Resistant Leukemia (2015) (0)
Expression analysis of 93 selected genes for prediction of treatment response in childhood acute lymphoblastic leukemia (ALL) (2009) (0)
62: High Resolution HLA Typing and ATG Prevent Children with all from GVHD and Treatment Related Mortality After Unrelated Donor Stem Cell Transplantation (2008) (0)
Second hematopoietic stem cell transplantation from unrelated donor in severe aplastic anemia. A retrospective analysis from the Aplastic Anemia Working party (SAA-WP). (2012) (0)
The Importance of Harmonizing Transplantation Procedures in Children with ALL: ALL-SCT-BFM 2003, a Prospective Multicenter Trial. (2007) (0)
Administration of Granulocyte Colony-Stimulating Factor Does Not Restore Defective Expression of bcl-2 and bcl-2-xL in Myeloid Progenitor Cells of Patients with Severe Congenital Neutropenia (Kostmann Syndrome). (2004) (0)
Allogeneic Hematopoetic Stem Cell Transplantation (SCT) In Children with ALL: Outcome of Matched Sibling Donor SCT (MSD-SCT) Is Equivalent to Unrelated Well Matched Donor HSCT (MD-HSCT) A Report From the Prospective International Multicenter Trial ALL-SCT-BFM 2003 (2010) (0)
TCF3-Hlf Hijacks ERG to Activate Leukemia-Critical Super-Enhancers in t(17;19) Leukemia (2017) (0)
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. (2023) (0)
Mitochondrial genome variants in non‐remitting ALL of childhood (2011) (0)
Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial AIEOP-BFM ALL 95 (2016) (0)
Stratification and prognosis of IGH-DUX4 positive acute lymphoblastic leukemia in children (2019) (0)
childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Late MRD response determines relapse risk overall and in subsets of (2013) (0)
ENCCA - EUROPEAN ACTIVITIES AND ACHIEVEMENTS WITH POTENTIAL INTEREST OUTSIDE OF EUROPE (2015) (0)
Prognostic Impact of Sex in Pediatric ALL in three consecutive ALL-BFM trials (2017) (0)
Gene expression analysis of NK cell receptors and their ligands in childhood acute lymphoblastic leukemia with involvement of the central nervous system (2015) (0)
Dendritic Cell Deficiencies in Pediatric Acute Lymphoblastic Leukemia Patients. (2005) (0)
3159 – PH-LIKE AND IKZF1PLUS FEATURES IN CHILDREN WITH DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKAEMIA (2022) (0)
Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome (2022) (0)
Pediatric T-Cell Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma: One and the Same or Two Different Diseases?. (2007) (0)
Die another way: necroptosis as alternative route to cell death (2017) (0)
Gain of Chromosome 21 Is Associated with Early Treatment Sensitivity in Childhood Acute Lymphoblastic Leukemia. (2005) (0)
The Expression of the Adaptor Protein SLP-65 Is Freqently Lost in Childhood B-Lineage Acute Lymphoblastic Leukemia (ALL). (2004) (0)
The Early Treatment Response of the Clinically Challenging Group of Childhood T-ALL without NOTCH1 Mutations Is Signified by a Specific mRNA Gene Profile. (2007) (0)
In standard and high risk acute lymphoblastic leukemias disease propagating cells are abundant and not confined to certain immunophenotypic fractions (2010) (0)
CD79a impacts central nervous system (CNS) infiltration of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) (2018) (0)
translocations in acute lymphoblastic leukemia Gene expression patterns associated with recurrent chromosomal (2013) (0)
Comparison of MRD Monitoring By IG/TR Rearrangement and BCR/ABL1 Transcript in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with Imatinib in the Esphall Study (2014) (0)
[DKG certification of paediatric cancer centres - a wide field …]. (2020) (0)
ORIGINAL ARTICLE Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients (2006) (0)
A mathematical approach to data evaluation with focus on prediction of minimal residual disease in pediatric ALL (2012) (0)
Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses (2018) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2019) (0)
Study )rearranged acute lymphoblastic leukemia: results from the Interfant-99 MLL ( mixed-lineage-leukemia poor prognostic subgroup of infants with Improved outcome with hematopoietic stem cell transplantation in a (2010) (0)
Trial NHL-BFM 90 Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored (2013) (0)
Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network (2019) (0)
Prognostic significance of minimal residual disease prior to reinduction in intermediate risk patients with ALL (2022) (0)
Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion (2017) (0)
Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia (2020) (0)
Gene Expression Analysis of Leukemic Blasts Persisting at Day 8 of Induction Therapy in Childhood ALL. (2004) (0)
Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study (2012) (0)
The Role of Activated NOTCH Signaling in Childhood T-ALL (2011) (0)
FOS and FOSB are linked with CNS-infiltration and inferior prognosis in childhood T-cell acute lymphoblastic leukemia (2019) (0)
leukemia patients. Results and conclusions of the multicenter trial Chemotherapy in 998 unselected childhood acute lymphoblastic (2011) (0)
The Combination of MRD and Copy Number Alterations (CNAs) Defines an Ultra-High Risk Group of Children with Primary T-Lymphoblastic Leukemia (T-ALL) (2016) (0)
Time to Leukaemia (TTL) Assessed in NOD/SCID Mice Transplanted with Primary ALL Leukaemia Cells Determines Early Relapse in Patients and Is Identified by a Specific Gene Signature. (2007) (0)
lymphoblastic leukemia interleukin 7, and early cytoreduction in vivo in childhood T-cell acute apoptotic cell death in context of maturation stage, responsiveness to In vitro susceptibility to dexamethasone- and doxorubicin-induced (2013) (0)
Prognostic relevance of the expression of genes associated with the P2RY8-CRLF2 fusion in acute lymphoblastic leukemia in childhood (2015) (0)
Abstract 4358: Analysis of the cell surface proteome for the identification of candidate diagnostic and therapeutic targets in drug resistant childhood acute lymphoblastic leukemia (ALL) (2010) (0)
HLA Identical Siblings Are the Best Donors for Children with ALL (2014) (0)
Prognostic Value of Immunophenotype In Infant ALL – Results of the INTERFANT'99 Study (2010) (0)
Methotrexate-associated toxicity during therapy of acute lymphoblastic leukemia in children with Down syndrome (2018) (0)
1407 The European Strategic Plan for children and adolescents with cancer (2015) (0)
TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL) (2021) (0)
Chemokine receptor expression in central nervous system (CNS) positive childhood acute lymphoblastic leukemia (2018) (0)
Targeted Deep Sequencing of Genetic Alterations Identified By Whole Exome Sequencing Reveals Clonal Evolution in Pediatric T-Lymphoblastic Leukemia (2014) (0)
Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia (2019) (0)
region of TEL and KIP1 the distinct regions of deletion on the short arm of chromosome 12 in Acute lymphoblastic leukemia of childhood: identification of two (2011) (0)
A Distinct DNA Methylation Pattern Characterizes Childhood Acute Lymphoblastic Leukemia and Separates Patients Into Prognostic Groups (2011) (0)
Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia. (2023) (0)
Ralph A. Reisfeld, PhD: In Memoriam (1926–2020) (2021) (0)
PCN135 CONTROLLING THE COST OF CARE OF BREAST CANCER PATIENTS IN GERMANY USING CLINICAL PATHWAYS (2010) (0)
Childhood Acute Lymphoblastic Leukemia: High Genomic Stability from Initial Diagnosis to Early Relapse. (2008) (0)
P305: COMPREHENSIVE TRANSCRIPTIONAL AND CYTOGENETIC PROFILING IMPROVES CLASSIFICATION AND DETECTION OF RISK-STRATIFYING MARKERS IN THE B-OTHER PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (2022) (0)
104 I-BFM SG trials on childhood ALL (2009) (0)
Single cell tri-channel-processing reveals structural variation landscapes and complex rearrangement processes (2019) (0)
Abstract 2957: CD127 is expressed by acute lymphoblastic leukemias and is efficiently targeted by the IL7R-antagonist OSE-127 through macrophage-mediated antibody dependent phagocytosis (2023) (0)
ORIGINAL ARTICLE The MLL recombinome of acute leukemias (2006) (0)
Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment (2011) (0)
Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia (2020) (0)
Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000 (2022) (0)
MRD-Detection by Multiparametric Flow Cytometry in Childhood Precursor B-Cell All:Predictive Impact of Early Blast Reduction Kinetics in Peripheral Blood (PB) on MRD-Level in Bone Marrow (BM) at Day 33 of the All-BFM2000 Potocol. (2004) (0)
Pediatric ALL relapses after allo (2020) (0)
p38α/β inhibition prevents ALL proliferation in vivo (2013) (0)
Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent (2015) (0)
Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia (2022) (0)
Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia (2017) (0)
[Acute leukemia in children]. (1993) (0)
An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia (2016) (0)
Notch Pathway Activation by a Combination of Activating NOTCH1-Receptor and Inactivating FBXW7 Mutations Robustly Predicts Excellent Early Treatment Response in Pediatric T-ALL. (2008) (0)
Non-Hodgkin Lymphoma in Adolescents: Experiences in 378 Adolescent NHL Patients Treated According to Pediatric NHL-BFM Protocols. (2009) (0)
Minimal Residual Disease (MRD) Analysis in Non-MRD Based ALL IC-BFM 2002 Protocol for Childhood ALL: Is It Possible To Omit Minimal Residual Disease in Risk Stratification?. (2006) (0)
Poor Prognosis in Children with ABL-Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols (2019) (0)
CD34+CD19−, CD34+CD19+ and CD34−CD19+ Cells May All Have Leukemia-Initiating Potential in NOD/Scid Mice. (2006) (0)
Significant Reduction of Treatment Related Mortality after Stem Cell Transplantation in 647 Children and Adolescents with ALL within BFM Trials during the Last 12 Years: A Long Term Analysis from 1996 to 2007 (2008) (0)
C20orf94 deletion is frequently associated with TEL/AML1 positive childhood ALL and mediated by illegitimate V(D)J recombination (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Martin Schrappe?

Martin Schrappe is affiliated with the following schools:

Humboldt University of Berlin
Kiel University
Hannover Medical School
Children's University
Heidelberg University

Martin Schrappe's Academic­Influence.com Rankings

Why Is Martin Schrappe Influential?

Martin Schrappe's Published Works

Published Works

What Schools Are Affiliated With Martin Schrappe?

Martin Schrappe's AcademicInfluence.com Rankings